Pharma Times
NOVEMBER 30, 2021
Following its recent approval of an injectable HIV-1 treatment from the National institute for Health and Care Excellence (NICE), GlaxoSmithKline (GSK) has high hopes in developing a cure for the virus in the future.
pharmaphorum
NOVEMBER 28, 2021
An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer – will get underway in the UK next year. The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
NOVEMBER 27, 2021
A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.
Outsourcing Pharma
NOVEMBER 29, 2021
The biotech firm has presented data from a study that could offer hope to patients with Parkinsonâs, Gaucher, Alzheimerâs and other neurodegenerative conditions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
NOVEMBER 29, 2021
Analyses provided by UK cancer charity Macmillan has provided insights into the repercussions experienced by patients waiting to receive treatment during the COVID-19 pandemic.
pharmaphorum
DECEMBER 2, 2021
The UK medicines regulator has approved GlaxoSmithKline and Vir Biotech’s antibody for COVID-19, Xevudy, which has been shown to be effective against the new Omicron strain of SARS-CoV-2 in lab testing. Xevudy (sotrovimab) is the second COVID-19 antibody to be approved by the MHRA after Roche/Regeneron’s Ronapreve (casirivimab and imdevimab), which got a green light during the summer.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
NOVEMBER 29, 2021
A leader from the health tech solutions company explains how progress in genetic testing has helped advance the detection and prevention of breast cancer.
Pharma Times
DECEMBER 2, 2021
Researchers have identified in those patients experiencing blood clots after vaccination a subsequent condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT).
pharmaphorum
DECEMBER 3, 2021
An online training academy that aims to raise the digital skills of NHS health and care workers is due to open its virtual doors next March, according to the Organisation for the Review of Care and Health Apps (ORCHA). The Digital Health Academy – developed with pharma company Boehringer Ingelheim – is part of a drive to get digital health tools and apps used more routinely in the management of health conditions, according to ORCHA.
NY Times
NOVEMBER 28, 2021
A “Frankenstein mix” of mutations raises concerns, but the variant may remain vulnerable to current vaccines. If not, revisions will be necessary.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
DECEMBER 2, 2021
An expert from the ]contract research organization discusses the impact virtual trials have had on the industry, and how that transformation is likely to continue.
Pharma Times
DECEMBER 1, 2021
The UK government has aimed to expand their COVID-19 vaccination programme, in accordance with guidance from the Joint Committee on Vaccination and Immunisation (JCVI).
pharmaphorum
NOVEMBER 30, 2021
The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priority review. AZ and partner Merck & Co have filed Lynparza (olaparib) for use in BRCA-mutated, HER2-negative early breast cancer in patients who have already been treated with chemotherapy either before or after surgery and are at high risk of the disease coming back.
Drug Patent Watch
NOVEMBER 30, 2021
Annual Drug Patent Expirations for FLOVENT+HFA Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from four suppliers. There are…. The post New patent expiration for Glaxo Grp drug FLOVENT HFA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
DECEMBER 1, 2021
Taken together, the provisions in the social policy bill represent the biggest step toward universal coverage since the passage of the Affordable Care Act.
Pharma Times
DECEMBER 2, 2021
Scientists and health experts have cautioned that the new variant could have the ability to bypass the effectiveness of vaccines that are currently available.
pharmaphorum
NOVEMBER 30, 2021
In the most recent of the Health Innovators video series, pharmaphorum’s founder, Dr Paul Tunnah, chats with the chief medical officer of Senseonics. Francine Kaufman discusses how Senseonics is helping patients monitor their diabetes with the first fully implantable long-term continuous glucose monitoring (CGM) system. Monitoring glucose values is necessary for diabetes patients, and technologically advanced systems make it much easier for patients to self-manage the disease, according to
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for OXTELLAR+XR Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Supernus Pharms drug OXTELLAR XR appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
DECEMBER 1, 2021
Taken together, the provisions in the social policy bill represent the biggest step toward universal coverage since the passage of the Affordable Care Act.
Pharma Times
DECEMBER 1, 2021
Amid the COVID-19 pandemic, the NHS faces staff and hospital equipment shortages alongside the growing need to reduce the backlog in patient surgeries and treatments.
pharmaphorum
DECEMBER 1, 2021
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at people manager effectiveness and how to boost team and co-worker engagement. It’s that special time in the annual corporate lifecycle: year-end performance reviews are being conducted around the globe, employee ratings allocated, calibrated and translated into salary increa
Outsourcing Pharma
DECEMBER 2, 2021
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
Drug Channels
NOVEMBER 30, 2021
ICYMI, CVS Health recently announced that it will close about 900 of its retail pharmacies. This downsizing complements the company’s shift toward its healthcare delivery future. This long-overdue move highlights the retail industry’s fundamental economic headwinds. The pharmacy shakeout is accelerating, as smaller competitors exit and larger companies reduce store count.
Pharma Times
NOVEMBER 30, 2021
The Scottish government aims to expand and advance their COVID-19 booster programme, following the six cases of the Omicron variant that were reported as of Monday 29 November. This decision is based on advice from the Joint Committee on Vaccination and Immunisation (JCVI).
pharmaphorum
DECEMBER 2, 2021
Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier drugs in the class. The drug – called UCB0599 – targets a protein called alpha synuclein that tends to get misfolded and accumulates into clumps in the brains of Parkinson’s patients, and is thought to damage neurons – somewhat analogous to amyloid and tau proteins in Alzheimer’s dise
Outsourcing Pharma
DECEMBER 1, 2021
An expert from the decentralized clinical trial solutions provider discusses how the virtual format and technology can help improve study representation.
NY Times
NOVEMBER 29, 2021
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
Pharma Times
DECEMBER 3, 2021
The news arrives after the tenth recorded positive Omicron case in Scotland, which the government has confirmed has no previous connection to the previous nine.
pharmaphorum
NOVEMBER 28, 2021
With governments around the world announcing measures to curb the new B.1.1.529 variant of COVID-19 – now christened Omicron – leading vaccine manufacturers have said they are poised to develop new shots if needed. News of the new variant emerged last week, and has resulted in travel bans being imposed on various African countries by the US, EU and UK, among others.
Outsourcing Pharma
DECEMBER 1, 2021
With the release of its new Sight OLO artificial intelligence based blood analyzer, Sight Diagnostics hopes to offer DCTs reliable, easy-to-use testing.
NY Times
NOVEMBER 30, 2021
The treatment, known as molnupiravir, could be authorized in the United States within days, and available within weeks, if the F.D.A. follows the committee’s recommendation.
Pharma Times
NOVEMBER 29, 2021
An additional six cases of the Omicron variant have now been detected in Scotland, bringing the UK total so far to nine.
pharmaphorum
NOVEMBER 30, 2021
Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved therapies from Johnson & Johnson and Takeda. There’s another $215 million tied to the achievement of regulatory and sales-based milestones with LNG-451, a compound that targets tumours with EGFR exon 20 mutations.
Outsourcing Pharma
DECEMBER 2, 2021
An expert from the contract research organization discusses the impact decentralized trials have had on the industry, and how that transformation is likely to continue.
NY Times
DECEMBER 2, 2021
In 2001, U.N. estimates suggested 150 million people would be infected with H.I.V. by 2021. That preceded an ambitious global campaign to curb the virus. How well did it work?
Expert insights. Personalized for you.
148 
Let's personalize your content